Literature DB >> 34999196

Peripheral and central kynurenine pathway abnormalities in major depression.

Elisabeth R Paul1, Lilly Schwieler2, Sophie Erhardt2, Sandra Boda3, Ada Trepci2, Robin Kämpe1, Anna Asratian4, Lovisa Holm4, Adam Yngve1, Robert Dantzer5, Markus Heilig6, J Paul Hamilton7, Martin Samuelsson6.   

Abstract

Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning. Pro-inflammatory cytokines facilitate metabolism of tryptophan along the kynurenine pathway (KP) putatively resulting in reduced neuroprotective and increased neurotoxic KP metabolites in MDD, in addition to modulating metabolic and immune function. This central nervous system hypothesis has, however, only been tested in the periphery. Here, we measured KP-metabolite levels in both plasma and cerebrospinal fluid (CSF) of depressed patients (n = 63/36 respectively) and healthy controls (n = 48/33). Further, we assessed the relation between KP abnormalities and brain-structure volumes, as well as body mass index (BMI), an index of metabolic disturbance associated with atypical depression. Plasma levels of picolinic acid (PIC), the kynurenic/quinolinic acid ratio (KYNA/QUIN), and PIC/QUIN were lower in MDD, but QUIN levels were increased. In the CSF, we found lower PIC in MDD. Confirming previous work, MDD patients had lower hippocampal, and amygdalar volumes. Hippocampal and amygdalar volumes were correlated positively with plasma KYNA/QUIN ratio in MDD patients. BMI was increased in the MDD group relative to the control group. Moreover, BMI was inversely correlated with plasma and CSF PIC and PIC/QUIN, and positively correlated with plasma QUIN levels in MDD. Our results partially confirm previous peripheral KP findings and extend them to the CSF in MDD. We present the novel finding that abnormalities in KP metabolites are related to metabolic disturbances in depression, but the relation between KP metabolites and depression-associated brain atrophy might not be as direct as previously hypothesized.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain volumetry; Central nervous system; Cerebrospinal fluid; Inflammation; Kynurenine pathway; Major depressive disorder; Structural magnetic resonance imaging

Mesh:

Substances:

Year:  2022        PMID: 34999196      PMCID: PMC9045681          DOI: 10.1016/j.bbi.2022.01.002

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   19.227


  65 in total

Review 1.  Inflammation-associated depression: from serotonin to kynurenine.

Authors:  Robert Dantzer; Jason C O'Connor; Marcus A Lawson; Keith W Kelley
Journal:  Psychoneuroendocrinology       Date:  2010-10-30       Impact factor: 4.905

2.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

3.  Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.

Authors:  Karen M Ryan; Kelly A Allers; Declan M McLoughlin; Andrew Harkin
Journal:  Brain Behav Immun       Date:  2019-10-10       Impact factor: 7.217

4.  Excitotoxicity of quinolinic acid: modulation by endogenous antagonists.

Authors:  K H Jhamandas; R J Boegman; R J Beninger; A F Miranda; K A Lipic
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.

Authors:  Kelly Doolin; Kelly A Allers; Sina Pleiner; Andre Liesener; Chloe Farrell; Leonardo Tozzi; Erik O'Hanlon; Darren Roddy; Thomas Frodl; Andrew Harkin; Veronica O'Keane
Journal:  Psychoneuroendocrinology       Date:  2018-05-19       Impact factor: 4.905

Review 6.  Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression.

Authors:  Yuri Milaneschi; Femke Lamers; Michael Berk; Brenda W J H Penninx
Journal:  Biol Psychiatry       Date:  2020-01-28       Impact factor: 13.382

7.  A meta-analysis of cytokines in major depression.

Authors:  Yekta Dowlati; Nathan Herrmann; Walter Swardfager; Helena Liu; Lauren Sham; Elyse K Reim; Krista L Lanctôt
Journal:  Biol Psychiatry       Date:  2009-12-16       Impact factor: 13.382

8.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

9.  The physiological action of picolinic Acid in the human brain.

Authors:  R S Grant; S E Coggan; G A Smythe
Journal:  Int J Tryptophan Res       Date:  2009-04-28

10.  A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder.

Authors:  C M Sellgren; M E Kegel; S E Bergen; C J Ekman; S Olsson; M Larsson; M P Vawter; L Backlund; P F Sullivan; P Sklar; J W Smoller; P K E Magnusson; C M Hultman; L Walther-Jallow; C I Svensson; P Lichtenstein; M Schalling; G Engberg; S Erhardt; M Landén
Journal:  Mol Psychiatry       Date:  2015-12-15       Impact factor: 15.992

View more
  2 in total

1.  Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study.

Authors:  Jonathan Savitz; Bart N Ford; Rayus Kuplicki; Sahib Khalsa; T Kent Teague; Martin P Paulus
Journal:  Psychopharmacology (Berl)       Date:  2022-10-22       Impact factor: 4.415

2.  Microbiome-Related Indole and Serotonin Metabolites are Linked to Inflammation and Psychiatric Symptoms in People Living with HIV.

Authors:  Nadira Vadaq; Yue Zhang; Elise Meeder; Lisa Van de Wijer; Muhammad Hussein Gasem; Leo Ab Joosten; Mihai G Netea; Quirijn de Mast; Vasiliki Matzaraki; Arnt Schellekens; Jingyuan Fu; André Jam van der Ven
Journal:  Int J Tryptophan Res       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.